Payment overview · 2025
General Payments
$391.00
19 reported records · 8 companies
Healthcare provider profile · identity verified
Scott J. Acosta, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARRERO, LA · NPI 1023018199
Verified facts
What the public records show
CMS Open Payments records show Scott J. Acosta, MD received $391.00 in general payments during 2025 across 19 reported records.
PFIZER INC. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.44 | 27.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $92.47 | 23.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.05 | 15.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $38.33 | 9.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.47 | 6.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.99 | 6.1% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $21.05 | 5.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.20 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $391.00 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $108.44 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $108.44 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $108.44 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $55.81 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.81 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| TheraSphere Administration Set Normalized: therasphere administration set |
Device | Boston Scientific Corporation | $16.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 233 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 881 | 237 |
| Gabapentin | Gabapentin | 676 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 643 | 170 |
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 166 |
| Losartan Potassium | Losartan Potassium | 530 | 132 |
| Metoprolol Succinate | Metoprolol Succinate | 491 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 484 | 140 |
| Alprazolam | Alprazolam | 472 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 438 | 127 |
| Omeprazole | Omeprazole | 420 | 112 |
| Clonazepam | Clonazepam | 349 | 69 |
| Metformin Hcl | Metformin Hcl | 323 | 87 |
| Lorazepam | Lorazepam | 307 | 64 |
| Tramadol Hcl | Tramadol Hcl | 295 | 98 |
| Lisinopril | Lisinopril | 272 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 263 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 69 |
| Simvastatin | Simvastatin | 246 | 68 |
| Furosemide | Furosemide | 242 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 236 | 38 |
| Celecoxib | Celecoxib | 234 | 60 |
| Eliquis | Apixaban | 233 | 45 |
| Ozempic | Semaglutide | 211 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 210 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 187 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 187 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 44 |
| Allopurinol | Allopurinol | 179 | 50 |
| Meloxicam | Meloxicam | 179 | 46 |
| Montelukast Sodium | Montelukast Sodium | 176 | 47 |
| Sertraline Hcl | Sertraline Hcl | 172 | 48 |
| Trazodone Hcl | Trazodone Hcl | 172 | 53 |
| Potassium Chloride | Potassium Chloride | 169 | 54 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 167 | 53 |
| Pregabalin | Pregabalin | 166 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 42 |
| Carvedilol | Carvedilol | 150 | 39 |
| Mirtazapine | Mirtazapine | 147 | 29 |
| Temazepam | Temazepam | 147 | 39 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 134 | 34 |
| Finasteride | Finasteride | 132 | 33 |
| Methylprednisolone | Methylprednisolone | 130 | 106 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 128 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 125 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 125 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 31 |
| Azelastine Hcl | Azelastine Hcl | 123 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 114 | 21 |
| Glipizide | Glipizide | 113 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 26 |
| Farxiga | Dapagliflozin Propanediol | 106 | 25 |
| Famotidine | Famotidine | 104 | 29 |
| Diazepam | Diazepam | 101 | 23 |
| Bupropion Xl | Bupropion Hcl | 99 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 18 |
| Mounjaro | Tirzepatide | 91 | 17 |
| Atenolol | Atenolol | 89 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 32 |
| Donepezil Hcl | Donepezil Hcl | 81 | 23 |
| Jardiance | Empagliflozin | 80 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | suppressed |
| Azithromycin | Azithromycin | 79 | 60 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 20 |
| Nifedipine Er | Nifedipine | 78 | 20 |
| Metformin Hcl Er | Metformin Hcl | 77 | 22 |
| Clonidine Hcl | Clonidine Hcl | 76 | 22 |
| Ezetimibe | Ezetimibe | 76 | 19 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 73 | 26 |
| Lovastatin | Lovastatin | 73 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 70 | 17 |
| Synthroid | Levothyroxine Sodium | 70 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 69 | 18 |
| Cefuroxime | Cefuroxime Axetil | 67 | 55 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 15 |
| Buspirone Hcl | Buspirone Hcl | 65 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 15 |
| Spironolactone | Spironolactone | 61 | 21 |
| Januvia | Sitagliptin Phosphate | 60 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 15 |
| Glimepiride | Glimepiride | 58 | 15 |
| Meclizine Hcl | Meclizine Hcl | 57 | 25 |
| Promethazine Hcl | Promethazine Hcl | 57 | 11 |
| Estradiol | Estradiol | 56 | 16 |
| Naproxen | Naproxen | 56 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 52 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 30 |
| Memantine Hcl | Memantine Hcl | 51 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | 14 |
| Mometasone Furoate | Mometasone Furoate | 48 | 26 |
| Risperidone | Risperidone | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 39 |
| Baclofen | Baclofen | 46 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 46 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 46 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 28 |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 11 |
| Ibuprofen | Ibuprofen | 39 | 18 |
| Benazepril Hcl | Benazepril Hcl | 38 | 15 |
| Glipizide Er | Glipizide | 38 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 12 |
| Myrbetriq | Mirabegron | 34 | 11 |
| Ondansetron Odt | Ondansetron | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 14 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Linzess | Linaclotide | 29 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 28 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | 13 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 12 |
| Prednisone | Prednisone | 27 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Lactulose | Lactulose | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 14 |
| Indapamide | Indapamide | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Azelaic Acid | Azelaic Acid | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $391.00 · 19 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, LINZESS, Natroba, PIFELTRO, PREVNAR 20, QULIPTA, SHINGRIX, Spinosad, TRELEGY ELLIPTA, TheraSphere Administration Set, TheraSphere Y90 Glass Microspheres 10 GBq, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error